JP2022521119A - 組織の灌流の増加における使用のためのイノシトールリン酸化合物 - Google Patents

組織の灌流の増加における使用のためのイノシトールリン酸化合物 Download PDF

Info

Publication number
JP2022521119A
JP2022521119A JP2021532911A JP2021532911A JP2022521119A JP 2022521119 A JP2022521119 A JP 2022521119A JP 2021532911 A JP2021532911 A JP 2021532911A JP 2021532911 A JP2021532911 A JP 2021532911A JP 2022521119 A JP2022521119 A JP 2022521119A
Authority
JP
Japan
Prior art keywords
compound
formula
group
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521119A5 (https=
Inventor
バッシッシ，モハンマド・フィラス
ロカ，カロリーナ サルセド
ベスタルド，フアン ペレロ
レイネス，ミゲル・ダビド フェレール
フェレール，マリア・デル・マール ペレス
Original Assignee
サニフィット・セラピューティクス・ソシエダッド・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サニフィット・セラピューティクス・ソシエダッド・アノニマ filed Critical サニフィット・セラピューティクス・ソシエダッド・アノニマ
Publication of JP2022521119A publication Critical patent/JP2022521119A/ja
Publication of JP2022521119A5 publication Critical patent/JP2022521119A5/ja
Priority to JP2024158993A priority Critical patent/JP2024175025A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021532911A 2019-01-30 2020-01-30 組織の灌流の増加における使用のためのイノシトールリン酸化合物 Pending JP2022521119A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158993A JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
EP19382061.0 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158993A Division JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Publications (2)

Publication Number Publication Date
JP2022521119A true JP2022521119A (ja) 2022-04-06
JP2022521119A5 JP2022521119A5 (https=) 2022-09-14

Family

ID=69770927

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532911A Pending JP2022521119A (ja) 2019-01-30 2020-01-30 組織の灌流の増加における使用のためのイノシトールリン酸化合物
JP2024158993A Pending JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158993A Pending JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Country Status (11)

Country Link
US (2) US20220000889A1 (https=)
EP (1) EP3917535A1 (https=)
JP (2) JP2022521119A (https=)
KR (1) KR20210148078A (https=)
CN (1) CN113365636A (https=)
AU (1) AU2020213713B2 (https=)
BR (1) BR112021014897A2 (https=)
CA (1) CA3130735A1 (https=)
IL (1) IL285084A (https=)
MX (1) MX2021008966A (https=)
WO (1) WO2020157362A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507430A (ja) * 1999-08-25 2003-02-25 ジーエムピー カンパニーズ，インコーポレーテッド 哺乳動物中で酸素運搬を向上する薬剤
JP2016514119A (ja) * 2013-03-15 2016-05-19 ラボラトリス サニフィット，エセ．エレ． 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
WO2017098047A1 (en) * 2015-12-11 2017-06-15 ETH Zürich Inositol derivatives for use in pathological crystallization

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001281071A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
BR112014007405B1 (pt) 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
JP6893037B2 (ja) 2015-12-11 2021-06-23 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507430A (ja) * 1999-08-25 2003-02-25 ジーエムピー カンパニーズ，インコーポレーテッド 哺乳動物中で酸素運搬を向上する薬剤
JP2016514119A (ja) * 2013-03-15 2016-05-19 ラボラトリス サニフィット，エセ．エレ． 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
WO2017098047A1 (en) * 2015-12-11 2017-06-15 ETH Zürich Inositol derivatives for use in pathological crystallization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NUTRIENTS, vol. Vol.10, 652, JPN6024040551, 2018, pages 1 - 17, ISSN: 0005429847 *
THE ANNALS OF THORACIC SURGERY, vol. 52, no. 4, JPN6023037062, 1991, pages 908 - 912, ISSN: 0005429845 *
日本血管外科学会雑誌, vol. 25, JPN6024017486, 2016, pages 359 - 365, ISSN: 0005429846 *
日衛誌, vol. 70, JPN6024040550, 2015, pages 211 - 219, ISSN: 0005429848 *

Also Published As

Publication number Publication date
IL285084A (en) 2021-09-30
CA3130735A1 (en) 2020-08-06
JP2024175025A (ja) 2024-12-17
BR112021014897A2 (pt) 2021-09-28
WO2020157362A1 (en) 2020-08-06
MX2021008966A (es) 2021-11-04
KR20210148078A (ko) 2021-12-07
US20230248749A1 (en) 2023-08-10
EP3917535A1 (en) 2021-12-08
US20220000889A1 (en) 2022-01-06
AU2020213713B2 (en) 2025-08-21
AU2020213713A1 (en) 2021-07-22
CN113365636A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
JP2024175025A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
US5780489A (en) Method for treating amyotrophic lateral sclerosis
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
JP2002518440A (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
RU2725626C2 (ru) Применение производных, содержащих связи с-о-р, у пациентов с почечной недостаточностью
JP7808029B2 (ja) 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物
HU184219B (en) Process for producing pharmaceutical compositions of aggragati on-inhiaiting activity
LU85639A1 (fr) Compositions pharmaceutiques et procede de preparation de compositions de phosphatidylserine utilisables au traitement de desordres du systeme nerveux central sans exercer d'effets sur la coagulation du sang
CN109771431A (zh) 和厚朴酚衍生物的新用途
AU750591B2 (en) Methods for the administration of amifostine
JP2022523402A (ja) 術後認知機能障害の予防及び治療のための化合物
EP0629405A1 (en) Agent for inhibiting a decrease in bone mass in renal osteodystrophy
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
KR102917330B1 (ko) 이소성 석회화의 치료를 위한 이노시톨 포스페이트
CN100430046C (zh) 用于治疗与年龄相关的疾病的组合物与方法
RU2425669C1 (ru) Средство для профилактики и лечения острого и хронического панкреатита
WO1999040919A1 (en) Remedies for cardiac dilastolic disorders
AU2003285351B2 (en) Agent having a destructive effect on malignant tumors and method for the production thereof
JP2001261555A (ja) 脳動脈中膜肥厚抑制剤
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP7257091B2 (ja) 認知症の治療及び予防薬
JP2021502328A (ja) 筋ジストロフィーを治療するためのエダサロネキセント投与計画
WO1999004783A1 (en) Composition for protection from damage by ischemia
JPH08208464A (ja) 高脂血症の治療及び予防薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240925

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241004

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251031